Downmodulation of the molecules involved in the inhibitory and regulatory pathways, such as CTLA‐4, PD‐1/PD‐L1, BTLA, LAG3, TIM3, TIGIT, and VISTA by specific antibodies or recombinant proteins should be used in the future for controlling diseases mediated by disturbed T cell‐associated immune responses such as those seen in RA. Here, BTLA is linked to rheumatoid arthritis.